Blog

Dec 19, 2024, 08:08

T790M resistance mutations in EGFR+ lung cancer – EGFR Positive Lung Cancer UK

EGFR Positive Lung Cancer UK shared on X:

“New research offers hope for those with T790M resistance mutations in EGFR+ lung cancer. Scientists have identified CDDO-Me, a compound that shows potential in preclinical studies to stop tumour growth.”

Machine learning-aided discovery of T790M-mutant EGFR inhibitor CDDO-Me effectively suppresses non-small cell lung cancer growth

Authors: Rui Zhou, Ziqian Liu, Tongtong Wu, Xianwei Pan, Tongtong Li, Kaiting Miao, Yuru Li, Xiaohui Hu, Haigang Wu, Andrew M. Hemmings, Beier Jiang, Zhenzhen Zhang, Ning Liu

T790M resistance mutations in EGFR+ lung cancer - EGFR Positive Lung Cancer UK

Andrew M. Hemmings Beier Jiang cancer EGFR Positive Lung Cancer UK Haigang Wu Kaiting Miao Ning Liu OncoDaily Oncology Rui Zhou Tongtong Li Tongtong Wu Xianwei Pan Xiaohui Hu Yuru Li Zhenzhen Zhang Ziqian Liu

VERITAC-2 Trial Update: Vepdegestrant Meets Primary Endpoint in ESR1-Mutant Breast Cancer

New Paper Alert: HARMONi-2 study of Ivonescimab vs pembrolizumab for PD-L1-positive non-small cell lung cancer

We are thrilled to welcome Dr. Jasmine Kamboj to the OncoDaily Editorial Board!

Oncologist Near Me – Fedro Alessandro Peccatori: Leading Expert in Gynecological Oncology

MATTERHORN trial - FLOT plus durvalumab will become the new standard of care in the preoperative setting for gastroesophageal cancer